Involvement of dysadherin and E-cadherin in the development of testicular tumours

Batistatou, Anna; Scopa, Chrisoula D.; Ravazoula, Panagiota; Nakanishi, Yukihiro; Peschos, Dimitrios; Agnantis, Niki J.; Hirohashi, Setsuo; Charalabopoulos, K.

doi:10.1038/sj.bjc.6602880

Cited by 28 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysadherin expression was detected in myoepithelial cells of ducts and acini, but not in non-neoplastic epithelial cells, as well as in endothelial cells of vessels and lymphocytes, as described previously (Batistatou et al, 2005(Batistatou et al, , 2006. Dysadherin immunostaining was observed in the membranes of the neoplastic cells and it was heterogeneous throughout the neoplasm ( Figure 1C).…”

Section: Ductal Carcinomasupporting

confidence: 63%

“…For the purposes of statistical analysis, as described previously (Shimada et al, 2004b;Batistatou et al, 2005), when more than 50% of tumour cells were stained for dysadherin, the tumour was evaluated as 'positive dysadherin expression (Dys( þ ))'. When less than 50% of tumour cells were stained for dysadherin, the tumour was evaluated as 'negative dysadherin expression (Dys(À))'.…”

Section: Evaluation Of the Stainingmentioning

confidence: 99%

“…It interacts with and modulates the properties of the Na þ , K þ ATPase (Ino et al, 2002;Lubarski et al, 2005). In human tissues increased dysadherin expression has been correlated with the development of metastasis and poor prognosis in gastric, pancreatic, colorectal, oesophageal, thyroid, tongue and cervical carcinomas, as well as in malignant melanoma (Aoki et al, 2003;Sato et al, 2003;Shimamura et al, 2003Shimamura et al, , 2004Nakanishi et al, 2004;Shimada et al, 2004a, b;Wu et al, 2004;Batistatou et al, 2005Batistatou et al, , 2006Nishizawa et al, 2005;Kyzas et al, 2006). Furthermore, in a small pilot series of breast cancer patients, dysadherin expression was correlated with poor prognosis (Ino et al, 2002).…”

Section: Dysadherin In Breast Carcinomamentioning

confidence: 99%

“…Furthermore, in a small pilot series of breast cancer patients, dysadherin expression was correlated with poor prognosis (Ino et al, 2002). In most of these neoplasms, as well as in testicular tumours and lymph node metastases of colorectal adenocarcinoma, increased dysadherin expression was correlated with reduced E-cadherin expression (Aoki et al, 2003;Sato et al, 2003;Shimamura et al, 2003Shimamura et al, , 2004Wu et al, 2004;Batistatou et al, 2005Batistatou et al, , 2006. In invasive ductal carcinoma, as reported in this study, there is an increase in dysadherin expression, which is not related to E-cadherin expression.…”

Section: Dysadherin In Breast Carcinomamentioning

confidence: 99%

“…This novel cancer-associated protein has been detected in head and neck, tongue, oesophageal, gastric, colorectal, testicular, pancreatic, thyroid, and cervical carcinomas as well as in malignant melanoma and has been associated with tumour aggressiveness (Ino et al, 2002;Tsuiji et al, 2002;Aoki et al, 2003;Sato et al, 2003;Shimamura et al, 2003Shimamura et al, , 2004Nakanishi et al, 2004;Shimada et al, 2004a, b;Wu et al, 2004;Batistatou et al, 2005;Nishizawa et al, 2005;Batistatou et al, 2006;Kyzas et al, 2006). A recent in vitro study has demonstrated that dysadherin has prometastatic effects that are independent of E-cadherin expression (Nam et al, 2006).…”

mentioning

confidence: 99%

See 4 more Smart Citations

In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin

et al. 2007

Self Cite

View full text Add to dashboard Cite

Reduction/loss of E-cadherin is associated with the development and progression of many epithelial tumours. Dysadherin, recently characterised by members of our research team, has an anti-cell -cell adhesion function and downregulates E-cadherin in a posttranscriptional manner. The aim of the present study was to study the role of dysadherin in breast cancer progression, in association with the E-cadherin expression and the histological type. We have selected ductal carcinoma, which is by far the most common type and lobular carcinoma, which has a distinctive microscopic appearance. Dysadherin and E-cadherin expression was examined immunohistochemically in 70 invasive ductal carcinomas, no special type (NST), and 30 invasive lobular carcinomas, with their adjacent in situ components. In ductal as well as in lobular carcinoma dysadherin was expressed only in the invasive and not in the in situ component, and this expression was independent of the E-cadherin expression. Specifically, all 10 (100%) Grade 1, 37out of 45(82.2%) Grade 2 and six out of 15 (40%) Grade 3 invasive ductal carcinomas showed preserved E-cadherin expression, while 'positive dysadherin expression' was found in six out of 10 (60%) Grade 1, 34 out of 45(75.5%) Grade 2 and all 15 (100%) Grade 3 neoplasms. None of the 30 infiltrating lobular carcinomas showed preserved E-cadherin expression, while all the 30 infiltrating lobular carcinomas exhibited 'positive dysadherin expression'. Dysadherin may play an important role in breast cancer progression by promoting invasion and, particularly in lobular carcinomas, it might also be used as a marker of invasion. Recent advances into molecular pathology of breast cancer have refined diagnostic accuracy and classification systems of the most common malignant neoplasm of women, rendering personalised therapy more possible. Today, there is a plethora of molecular genetic data that indicate differences in pathogenesis between the various types of breast carcinomas and thus support their categorisation, to the patient benefit. The demonstration of lack of E-cadherin expression in lobular neoplasms has had a sound impact with practical applications (Mastracci et al, 2005) In about half of lobular carcinomas, loss of E-cadherin involves genetic changes, that is loss of heterozygosity (LOH) at 16q22.1, while in the other half epigenetic events are involved (Knudsen and Wheelock, 2005;Mastracci et al, 2005). Ductal carcinomas, on the other hand, express E-cadherin, albeit in reduced levels and/or in abnormal cellular locations (Knudsen and Wheelock, 2005). Reduction/loss of E-cadherin has been associated with the development and progression of many epithelial neoplasms. Aberrant E-cadherin expression (heterogeneous, cytoplasmic, or absent) has been detected immunohistochemically in several cancers, including head and neck carcinoma, gastric adenocarcinoma, lobular breast carcinoma, lung cancer, colorectal carcinoma, prostate adenocarcinoma, pancreatic, and bladder cancer (Becker et

show abstract

Section: Ductal Carcinomasupporting

confidence: 63%

Section: Evaluation Of the Stainingmentioning

confidence: 99%

Section: Dysadherin In Breast Carcinomamentioning

confidence: 99%

Section: Dysadherin In Breast Carcinomamentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma

et al. 2006

View full text Add to dashboard Cite

Reduction/loss of E-cadherin is associated with the development and progression of many epithelial tumors, while in a limited number of neoplasms, E-cadherin is re-expressed in metastases. Dysadherin, recently characterized by members of our research team, has an anti-cell-cell adhesion function and downregulates E-cadherin in a posttranscriptional manner. Colorectal cancer (CRC) is one of the most common tumors in the developed world, and lymph node metastases are harbingers of aggressive behavior. The aim of the present study was to examine the dysadherin and E-cadherin expression patterns in lymph node metastases vs primary CRC. Dysadherin and E-cadherin expression was examined immunohistochemically in 78 patients with CRC, Dukes' stage C in the primary tumor and in one lymph node metastasis. Dysadherin was expressed in 42% while E-cadherin immunoreactivity was reduced in 45% of primary tumors. In lymph nodes, 33 and 81% of metastatic tumors were positive for dysadherin and E-cadherin, respectively. Dysadherin expression was not correlated with E-cadherin expression in the primary tumor with a reverse correlation evident in the lymph node metastases. Our results suggest that different mechanisms govern E-cadherin expression in the primary tumor and the corresponding lymph node metastases.

show abstract

Expression of adhesion molecules during normal pregnancy

et al. 2007

View full text Add to dashboard Cite

We review the available information regarding the role of adhesive molecules as potential participants in the complex events of fertilization, embryogenesis, implantation and placentation. Studies that specifically relate to the expression and modulation of adhesive molecules in fertilization, embryogenesis, and implantation have been identified in the literature and by Medline searches. Cell-cell and cell-extracellular matrix interactions play a critical role in various developmental processes and in the cascade of events that lead to implantation and to the normal development of the fetus during pregnancy. Adhesion molecules influence, directly or indirectly, numerous aspects of cell behaviour, cell migration, cell growth, cell survival, cell proliferation, angiogenesis, invasion and metastasis.

show abstract

Involvement of dysadherin and E-cadherin in the development of testicular tumours

Cited by 28 publications

References 24 publications

In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin

In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin

Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma

Expression of adhesion molecules during normal pregnancy

Contact Info

Product

Resources

About